Our study demonstrated the potential of HMGB1 as a biomarker for predicting therapeutic efficacy of anti-PD-1/PD-L1 antibody monotherapy in the patients with NSCLC expressing PD-L1 TPS ≥ 50%. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.